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Key points
 Cardiospheres (CSps) are a promising new form of cardiac stem cells with advantage over other
stem cells for myocardial regeneration, but direct implantation of CSps by conventional routes
has been limited due to potential embolism.
 Wehave implanted CSps into the pericardial cavity and systematically demonstrated its efficacy
regarding myocardial infarction.
 Stem cell potency and cell viability can be optimized in vitro prior to implantation by
pre-conditioning CSps with pericardial fluid and hydrogel packing.
 Transplantation of optimized CSps into the pericardial cavity improved cardiac function and
alleviated myocardial fibrosis, increased myocardial cell survival and promoted angiogenesis.
 Mechanistically, CSps are able to directly differentiate into cardiomyocytes in vivo and promote
regeneration of myocardial cells and blood vessels through a paracrine effect with released
growth factors as potential paracrine mediators.
 These findings establish a new strategy for therapeutic myocardial regeneration to treat myo-
cardial infarction.
Abstract Cardiospheres (CSps) are a new form of cardiac stem cells with an advantage over other
stem cells for myocardial regeneration. However, direct implantation of CSps by conventional
routes to treat myocardial infarction has been limited due to potential embolism. We have
implanted CSps into the pericardial cavity and systematically assessed its efficacy on myocardial
infarction. Preconditioning with pericardial fluid enhanced the activity of CSps and matrix
hydrogel prolonged their viability. This shows that pretransplant optimization of stemcell potency
and maintenance of cell viability can be achieved with CSps. Transplantation of optimized CSps
into the pericardial cavity improved cardiac function and alleviated myocardial fibrosis in the
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non-infarcted area, and increased myocardial cell survival and promoted angiogenesis in the
infarcted area. Mechanistically, CSps were able to directly differentiate into cardiomyocytes in
vivo and promoted regeneration ofmyocardial cells and blood vessels in the infarcted area through
a paracrine effect with released growth factors in pericardial cavity serving as possible paracrine
mediators. This is the first demonstration of direct pericardial administration of pre-optimized
CSps, and its effectiveness on myocardial infarction by functional and morphological outcomes
with distinct mechanisms. These findings establish a new strategy for therapeutic myocardial
regeneration to treat myocardial infarction.
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Introduction
Ischaemic heart disease associated withmyocardial infarc-
tion is the leading cause of mortality (Mozaffarian et al.
2015). Although revascularization therapy can improve
the survival of patients with myocardial infarction, it
cannot resolve ventricular remodelling and heart failure as
a result of myocardial damage (St John Sutton et al. 2003;
Daubert et al. 2015). How to regenerate myocardial cells
and make up the loss caused by myocardial infarction is a
pressing medical issue. Experimental and clinical studies
show that stem cell therapy can improve cardiac function
and prognosis (Fisher et al. 2015).
Many sources of stem cells have been used in
experimental models and clinical trials of myocardial
infarction, including bone marrow-derived stem cells or
skeletal myoblast-derived stem cells, and more recently
stem cells derived from the heart. While bone marrow-
derived cells do not engraft well over the long term,
skeletal myoblast-derived stem cells are pro-arrhythmic.
Cardiac stem cells may offer advantage over extracardiac
stem cells in differentiating into cardiac myocytes and
better survival in the myocardium (Messina et al. 2004;
Bearzi et al. 2007). How to apply these cells effectively in
myocardial regeneration is of intense interest.
Cardiospheres (CSps) are a particular form of stem cells
derived in vitro from in situ stem cells of cardiac tissue. The
structure of CSps mimics the niche microenvironment of
cardiac stem cells in vivo with undifferentiated cardiac
stem cells in the core and cardiac-committed cells on the
outer layer (Chimenti et al. 2010). This gradient structure
is beneficial to the survival of stem cells and maintenance
of their ‘stemness’. Intact, stem cell-containing CSps are
different from isolated stem cells derived from the CSps
(cardiosphere-derived cells, CDCs) (Barile et al. 2013)
and produce stronger paracrine effects than the latter,
and have the ability to directly differentiate into myo-
cardial cells (Davis et al. 2010; Barile et al. 2013), and
thus have greater potential for myocardium regeneration.
However, they are small particles in nature. This limits
the pathways for transplantation in vivo due to potential
embolism. The conventional delivery routes are not well
suited to implantation of CSps and are associated with
very low survival rates in the heart tissue (Hou et al.
2005). The pericardial cavity is a double-walled sac, which
would prevent stem cells and spheres from entering the
blood circulation, but proteins with a molecular mass
below 40 kDa can diffuse through the epicardium into
the pericardial space (Limana et al. 2010), which allows
paracrine communications. We hypothesize that intra-
pericardial delivery is an effective way for direct CSps
transplantation, which allows safe implantation, avoids
the risk of entry into the bloodstream and produces a
regenerative effect. We reason that pericardial cavity also
allows the transplanted stem cells to be preconditioned
or pre-treated in order to generate better therapeutic
effects after transplantation. Our second hypothesis is
that the activity of CSps can be further improved by
pericardial fluid (PF) obtained from another subject
preconditioned with myocardial infarction, as PF from
human withmyocardial infarction, when injected into the
pericardial cavity in mice, can increase the expression of
stem cell genes, especially c-kit, in epicardium (Limana
et al. 2010). Therefore, the present study aimed first to
enhance the efficacy of CSps by pretreatmentwith PF from
rats with myocardial infarction (PFMI) and secondly to
assess the therapeutic effect on myocardial infarction by
administering these functionally enhanced CSps into the
pericardial cavity. One challenge in cell transplantation is
how to maintain the activity of stem cells during trans-
fer from the laboratory to the operating theatre (Hanna &
Hubel, 2009; Schoenhard&Hatzopoulos, 2010). A further
objective was therefore to improve the survival of CSps
in vitro before transplantation, by packaging CSps with
matrix hydrogel before in vivo application.
We therefore first evaluated the effects of different
concentrations of PFMI on CSps in vitro, and selected
the most efficacious CSps as the target stem cells. We
then assessed the protective effect of matrix hydrogel on
the survival of CSps in vitro. The selected most potent
CSps packaged bymatrix hydrogel were then transplanted
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into the pericardial cavity in rats undergoing myocardial
infarction. The survival and outcome of CSps, the effect
of its transplantation on myocardial infarction and the
possible mechanisms were examined.
Methods
CSps culture
Specimen preparation, CSps culturing and harvesting
were performed according to a previously published
method (Stastna et al. 2010), but with a different culture
medium for CSps. Briefly, cardiac tissue specimens from
the septum of the left ventricle of SD rats (male, 3 weeks
old) were cut into small pieces, washed in PBS three times,
partially enzymatically digested and grown in primary
cultures as explants on poly-D-lysine (Sigma, St. Louis,
MO, USA) coated dishes in complete explant medium
(CEM). The CEMmedium consisted of Iscove’s modified
Dulbecco’s medium (Corning, Corelle, NY, USA)
supplemented with 10% FBS (Corning), 1% penicillin-
streptomycin, 1% l-glutamine and 0.1 mmol l−1
2-mercaptoethanol, at 37°C and 5% CO2. The culture
medium was replaced every 2–3 days. After 1–2 weeks,
round phase bright cells, migrating over a layer of
fibroblast-like cells derived from explants, were harvested
by mild trypsinization and seeded at about 7 × 104
cells cm−2 onto poly-D-lysine coated wells in CEM. About
1 week after plating, CSps of passage 0 (P0) were collected
for passage. The number of CSps per generation was
recorded.
Immunofluorescence staining
Cells were incubated with the primary antibodies at
4°C overnight. These primary antibodies were anti-c-kit
(ab8295), anti-sca-1 (ab4336) and anti-KDR (ab9530)
(Abcam, Cambridge,MA, USA). After being washed three
timeswithPBST, cellswere incubatedwithAlexa Fluor 488
goat anti-mouse (A11001, Invitrogen,Carlsbad, CA,USA)
orAlexa Fluor 594 goat anti-rabbit (AB6939, Abcam) anti-
bodies in 1%BSA for 1 h at room temperature in the dark.
A laser scanning confocal microscope (Nikon Eclipse Ti,
Nikon, Tokyo, Japan) and the supplier software were used
for imaging and analysis.
Effect of PFMI on CSps
The PF was aspirated under sterile conditions from 10 rats
that were euthanized 4 days after myocardial infarction,
centrifuged for 10 min at 3000 g at 4°C, mixed together
and passed through a 0.22 μm filter to remove cell debris.
Cell suspensions of CSps were passaged at a density of
5000 cells cm−2 in 96-well plates, and CSps were formed
again after 3 days. Different concentrations of PF were
added (0, 25, 50 and 100%), and after 24 h of culture,
CSps were made into single cell suspensions and seeded
to the plates in culture medium (without phenol-red).
Cell activity was detected according to the CCK-8 (Sigma)
operation manual and absorbance was read at 450 nm.
CSps were collected, and gene expression levels of VEGF,
bFGF, FGF, IGF-1, cTnT, c-kit, sca-1 and KDR were
detected by quantitative RT-PCR (qRT-PCR).
Quantitative RT-PCR
mRNA levels of VEGF, bFGF, HGF and IGF-1were
determined by qRT-PCR. In brief, total RNA was
extracted from cultured CSps using Trizol reagent
(Invitrogen) as per the manufacturer’s instructions. RNA
was reverse transcribed to cDNA using a PrimeScriptTM
RT reagent kit (TaKaRa, Dalian, China). Reverse
transcription was performed at 37°C for 15 min and
85°C for 5 s. Real-time PCR amplification was performed
using a LightCycler 480 Real-Time PCR System (Roche,
Switzerland). After amplification, a melting curve was
acquired by heating at 4°C s–1 to 95°C, cooling at 4°C s–1
to 70°C, maintenance at 70°C for 20 s, and then slowly
heating at 4°C s–1 to 95°C to determine the specificity of
PCR products. All qRT-PCR data were normalized to the
reference gene GAPDH. The PCR primer sequences were
as follows: VEGF, 5’-CGACAGAAGGGGAGCAGAAA-3’
(forward primer) and 5’-GCTGGCTTTGGTGAGGTTT
G-3’(reverse primer); bFGF, 5’-GATCCCAAGCGGCT
CTACTG-3’ (forward primer) and 5’-CCGTGACCGGT
AAGTGTTGT-3’(reverse primer); HGF, 5’-CCTT
CGAGCTATCGCGGTAA-3’ (forward primer) and 5’-G
AATTTGTGCCGGTGTGGTG-3’(reverse primer); IGF-1,
5’-CAAAATGAGCGCACCTCCAA-3’ (forward primer)
and 5’-CTTCAGCGGAGCACAGTACA-3’(reverse prim-
er); GAPDH, 5’-AAGGTCGGAGTCAACGGATTT-3’
(forward primer) and 5’-AGATGATGACCCTTTTGGC
TC-3’(reverse primer); c-kit, 5’-AATCCGACAAC
CAAAGCAAC-3’ (forward primer) and 5’-ACCACA
GGTTGAGACTACAGT-3’(reverse primer); sca-1, 5’-AA
CCATATTTGCCTTCCCGTCT-3’ (forward primer) and
5’-CCAGGTGCTGCCTCCAGTG-3’(reverse primer);
KDR, 5’-ATTCTGGACTCTCCCTGCCTA-3’ (forward
primer) and 5’-TGTCTGTCTTGGCTGTCATCTG-3’(re
verse primer); c-TnT, 5’-AGAGGACTCCAAACCC
AAGC-3’ (forward primer) and 5’-ATTGCGAATACGCT
GCTGTT-3’(reverse primer).
DiR label and preparation of matrix hydrogel CSps
suspension
CSps were labelled with 3.5 μg mL−1 of 1,1′-dioc-
tadecyl-3,3,3′-tetramethylindotricarbocyanine iodide
(DiR, Caliper Life Sciences, Waltham, MA, USA) by
addition of the dye into cells suspended in PBS (Granot
et al. 2007). After 30 min of incubation at 37°C, cells
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were extensively washed in PBS. About 5 × 106 cells were
collected in the centrifuge tube. Then, 100 μl matrix
hydrogel (1:2 dilution) (Corning) was added to the tube
and mixed thoroughly.
Flow cytometry analysis
Cell apoptosis andnecrosiswere assessedusing anAnnexin
V-FITC/PI apoptosis kit (Life Technologies Inc., Carlsbad,
CA, USA) as per the manufacturer’s instructions. Cells
were divided randomly into six groups: CSps were
collected in PBS at three time points (PBS 1 h, PBS
3 h, PBS 6 h) or in Matrix hydrogel at the same time
points (Matrigel 1 h, Matrigel 3 h, Matrigel 6 h). At each
time point, CSps were washed in PBS and dissociated to
generate single cell suspensions. The cells were incubated
with 5 μL Annexin V and 5 μL PI (Becton Dickinson,
Franklin Lakes, NJ, USA) for 10 min at room temperature
in the dark. Cells from each sample were then analysed
using a FacsCalibur flow cytometer (Becton Dickinson).
The data were analysed using CELLQuest software
(Becton Dickinson). The results were interpreted as
follows: cells in the lower-left quadrant (Annexin-V−/PI−)
represent living cells; those in the lower-right quadrant
(Annexin-V+/PI−) represent early apoptotic cells; those
in the upper-right quadrant (Annexin-V+/PI+) represent
late apoptotic cells; and those in the upper-left quadrant
(Annexin-V−/PI+) represent necrotic cells. Experiments
were repeated at least three times independently.
Experimental protocol and animal surgery
All animal handling and procedures were performed in
accordance with the protocols for these studies approved
by Animal Ethics Committee of Sun Yat-sen University.
All animals received humane care in compliance with
the Guide for the Care and Use of Laboratory Animals
(National Institutes of Health, revised 1996). Surgery was
performed under deep anaesthesia and every attempt
was made to minimize pain and discomfort. Left
coronary artery occlusion was performed in SD rats
(female, 250–280 g) as previously described (Zhang
et al. 2010). Briefly, after anaesthesia by intraperitoneal
administration of pentobarbital sodium (30 mg kg−1,
Sigma), all animals underwent endotracheal intubation.
Mechanical ventilation was provided with room air at 60
to 70 breaths min–1 using a Rodent Respirator (Taimeng
Company, Chengdu, China). A standard lead-II ECG
was recorded via subcutaneous stainless-steel electro-
des. After a left thoracotomy was performed to expose
the heart at the fifth intercostal space, the left anterior
descending coronary artery was ligated with a 6-0 silk
suture. Ischaemia was confirmed by the elevation of ST
segment in ECG and cardiac cyanosis. After these surgical
procedures, rats were allowed to stabilize for 15 min.
Matrigel CSps suspensions (0.1 mL) or blank Matrigel
were injected in the pericardial cavity through the trocar
(24 G, B. Braun Melsungen AG, Melsungen, Germany).
The pericardial membrane was then sutured to close the
pericardial cavity. The sham-operated rats underwent the
same operative procedures, but the suture was loosely tied
to avoid coronary artery occlusion. The rats undergoing
myocardial infarction operation were divided into three
groups: CSps group (n = 25), Control group (n = 25)
and Sham group (n = 25). Rats were given Matrigel CSps
suspensions (5 × 106 cells) for the CSps group, and blank
Matrigel only for the Control and Sham groups.
Small animal in vivo imaging technology
Xenogen’s IVIS 100 Series Imaging System (Alameda, CA,
USA) and Olympus SZX12 (Tokyo, Japan) microscope,
coupled with a Pixelfly QE (PCO, Kelheim, Germany)
charge-coupled device (CCD) camera, were used to
monitor localization of DiR-labelled CSps within live
animals (Kalchenko et al. 2006). Imaging was performed
1, 2 and 4 weeks after CSps injection, and the survival
rate of CSps was calculated by dividing the fluorescence
value ofDiR at each time point with that immediately after
injection. The excitation and emission filters in the IVIS
system were set at 760 and 810 nm, respectively. Image
processing and data analysis were performed using Living
Image 2.5 software and ImageJ version 1.34 (W. Rasband,
National Institutes of Health, Bethesday, MD, USA). The
experiments were repeated in at least six different animals
per group.
Functional evaluation of the left ventricle
Transthoracic echocardiography (ultrasound cardio-
graphy, UCG) was performed with animals anaesthetized.
Two-dimensional short- and long-axis images of the
left ventricle were obtained at the papillary muscle
level (ULTRAMARK 9, Philips, USA). The following
parameters were measured: left ventricular anterior wall
thickness (AWT), left ventricle end-systolic dimension
(LVESD) and left ventricle ejection fraction (LVEF). Four
different time points were selected for echocardiographic
studies: before (before the surgical procedure), and 1, 2
and 4 weeks after myocardial infarction.
Small-animal PET/CT scanning
At 4 weeks after myocardial infarction, positron emission
tomography (PET) and image analysis were performed
using an Inveon micsoPET scanner (Siemens Medical
Solutions, Erlangen, Germany) (Gao et al. 2012).
Animals were anaesthetized as described above, and
approximately 100 μCi 100 g−1 body weight of 2-deoxy-
2-[fluorine-18]fluoro-D-glucose (F-FDG, gift from the
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First Affiliated Hospital of Sun Yat-sen University) was
administered via tail vein injection. For each scan,
regions of interest (ROIs) were drawn using the software
on decay-corrected whole-body coronal images. Radio-
activity levels within the myocardiumwere obtained from
mean pixel values within the multiple ROI volumes and
then converted to MBq mL–1. These values were then
divided by the administered activity to obtain (assuming
a tissue density of 1 g mL−1) an image ROI-derived
percentage injected dose per gram (%ID g–1). The ability
to uptake F-FDG in the infarct zone represents the number
of viable myocardial cells.
Tissue processing and staining
For histological analysis, six animals per group were
sacrificed (via with an overdose of pentobarbital sodium)
at 4 weeks after myocardial infarction and CSps trans-
plantation. Hearts were quickly removed and fixed with
4% paraformaldehyde for Masson tri-chrome stain and
immunohistochemistry.
The components of cardiac tissue were identified
according to their colour by Masson stain: blue for
collagen fibres and red for myocytes. Myocardial infarct
size was measured as the percentage of the left ventricle
circumference occupied by scar tissue in the mid-left
ventricle tissue section slices. Collagen volume fraction
(CVF) was determined using an HPISA 100 chromatic
colour pathological analysis system (Olympus) using five
random images from each slide and five slides per sample,
and the mean values of CVF were obtained by one
investigator blinded to the experimental groups.
For immunohistochemistry, transverse myocardial
sections (4 μm thick) were deparaffinized and treated
with 0.3% hydrogen peroxide and then blocked with
10% normal serum (homologous with the primary anti-
bodies) for 30 min at room temperature. The following
primary antibodies were used: cTnT (ab8295, Abcam) and
a-SMA (ab7817, Abcam). The ROI of cTnT was used to
evaluate myocardial cells in the infarcted region. Arterio-
lar density (arterioles per field) was quantified in a similar
way after staining with α-SMA in separate sections. In
each rat heart, 3 sections were chosen and in every section
three fields were randomly selected for computerized
planimetry. After staining, the average positive area was
calculated by computer-assisted planimetry (Image-Pro
Plus 6.0, Media Cybernetics, Silver Springs, MD, USA).
5-Bromo-2-deoxyuridine (BrdU, Sigma, B5002) was used
to detect the proliferation of new cells in vivo after myo-
cardial infarction. Each group of rats was given BrdU
(I.P. injection, 100 mg kg day−1) for 4 weeks after myo-
cardial infarction. Paraffin sections of cardiac tissue were
de-waxed and rehydrated, and the antigen was retrieved.
The sliceswere then incubated in diluted hydrochloric acid
for 30min to denatureDNA.Thereafter, the tissue sections
were blocked using 10% goat serum for 1 h, incubated
with primary BrdU antibody (Abcam, ab8039) in 1:1000
dilution overnight at 4°C, followed by incubation with
secondary antibody (Invitrogen, A10521) for 2 h at room
temperature. The nucleus was labelled by Hoechst 33258.
ELISA
Pericardial fluid was directly collected 1 week after
myocardial infarction, and pericardial lavage fluid was
collected after 4 weeks. Four weeks after myocardial
infarction, animals were anaesthetized and underwent
endotracheal intubation. Mechanical ventilation was
provided using a Rodent Respirator in order to keep the
heart beating. Then, 100 μl sterile double distilled water
was injected into the pericardial cavity, and the fluid was
collected after beingmixed by the heart beating for 10min.
The levels of VEGF, bFGF, HGF and IGF-1 in PF or peri-
cardial lavage fluid were measured by an enzyme-linked
immunosorbent assay (ELISA; R&D, Minneapolis, MN,
USA), according to the instructions supplied.
Statistical analysis
All data are expressed asmean±SD. Statistical analysiswas
performed with SPSS 13.0. One-way ANOVA was used to
evaluate differences among three groups or a t test between
two groups. Two-way ANOVA was used to analyse the
difference among three groups at multiple time points. A
value of P < 0.05 was considered statistically significant.
Results
Characteristics of CSps in vitro
The characteristics of CSps in vitro are shown in Fig. 1. In
Fig. 1A, CSps were formed as three-dimensional spheres
in the culture in vitro. Expression of the cardiac stem cells
markers is shown in Fig. 1B. It can be seen that c-kit, sca-1
and KDR were all expressed in the interior of CSps, which
simulates the niche structure of cardiac stem cells in the
growthmicroenvironment in vivo. However, the locations
of the three markers in the CSps were different; c-kit
and KDR were not fixed, but sca-1 was always expressed
in the centre of CSps. We also noticed that the cells
expressing any one of the three markers, c-kit, sca-1 and
KDR, would certainly form CSps, and none of the three
markers was expressed in the monolayer cells (data not
shown). Figure 1C shows the difference in the amount of
CSps generated in different culture passages. There was no
significant difference in the number of clones between P1
(56 ± 7), P2 (55 ± 8) and P0 (58 ± 5). However, from
P3 (45 ± 6), the number of clones gradually decreased
(35 ± 5 for P4 and 56 ± 7 for P5), and the difference was
statistically significant (P < 0.05). In the present study,
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passages P0–P5 of CSps were collected to measure the
gene expression level of the growth factors by qRT-PCR.
Figure 1D shows the expression levels of growth factors
VEGF, bFGF, HGF and IGF-1, in different passages of
CSps. From P3, the expression of VEGF (80 ± 6%), bFGF
(78 ± 5%), HGF (77 ± 6%) and IGF-1 (78 ± 6%)
was significantly reduced, but there was no significant
difference among P1, P2 and P0. According to the above
results, the P2 generation of CSps was selected as the
candidate stem cells for transplantation in vivo.
Protective effect of matrix hydrogel on CSps in vitro
The protective effect of matrix hydrogel on CSps in vitro
is shown in Fig. 2. At 4°C, CSps in the PBS control group
began to be apoptotic after 1 h in vitro, and the proportion
of living cells continued to decrease with time. After 1, 6
and 12 h, the proportion of living cells in good condition
was only 92.81 ± 1.48, 86.35 ± 1.65 and 44.48 ± 1.45%,
respectively. Compared with the PBS control group,
the survival rate of CSps in the matrix hydrogel was
significantly increased. The proportions of living CSps
were 95.41 ± 1.83, 93.55 ± 1.36 and 92.38 ± 1.43%,
respectively, after 1, 6 and 12 h in vitro at 4°C.
Effect of PFMI on the biological characteristics of CSps
Figure 3 shows the effect of different concentrations of
PFMI on the biological characteristics of CSps. Figure 3A
shows the effect on the viability of CSps. There was
no significant effect on cell viability after pretreatment
with 25 and 50% PFMI, although the cell viability of
CSps was slightly decreased after pretreatment with 100%
PFMI (P < 0.05). The results from Fig. 3B show that
all concentrations of PFMI pretreatment were able to
enhance the gene expression of c-kit, sca-1 and KDR.
The effect was significantly greater with 50 and 100%
PFMI pretreatment (P < 0.05, vs. 25% PFMI); however,
there was no significant difference between 50 and 100%
PFMI pretreatment. As shown in Fig. 3C, pretreatment of
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Figure 1. Characteristics of CSps in culture
A, morphology of CSps in in vitro culture (P2 generation); B, number of CSps generated in different passages
(n = 10 dishes per generation); C, expression of c-kit, sca-1 and KDR in CSps by immunofluorescence staining
(n = 5); D, gene expression levels of VEGF, bFGF, HGF and IGF-1 in different culture passages by real-time
quantitative PCR (n = 3 per generation). ∗P < 0.05 versus P0.
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Figure 2. Protective effect of matrix hydrogel on CSps
A, survival, apoptosis or death of CSps detected by flow cytometry; B, averaged data of survival, apoptosis or
death of CSps and statistical analysis. ∗P < 0.05 versus PBS 1 h group; #P < 0.05 versus PBS groups at the same
time points.
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PFMI promoted cTnT mRNA expression, with a greater
effect for 50 and 100% PFMI (P < 0.05, vs. 25% PFMI).
Figure 3D shows that PFMI pretreatment promoted the
mRNA expression of VEGF, bFGF, HGF and IGF-1 in
CSps. Compared with 25% PFMI, 50 and 100% PFMI
produced a stronger effect (P < 0.05). All the data
in Fig. 3 demonstrate that PFMI at all concentrations
generally enhanced the expression ofmajor stem cell genes
and cardiac muscle-specific genes of CSps, and also the
expression of growth factors, hence indicating a higher
biological activity of CSps with minimal adverse effects
on cell viability. In particular, 50% PFMI pretreatment
was able to significantly enhance the biological activity
of CSps, but had no significant effect on cell viability.
This concentration of CSps was therefore used for in vivo
experiments.
Survival and outcome of CSps after transplantation
in vivo
The in vivo survival rate of DiR-labelled CSps at different
time points was detected using a small animal in vivo
imaging technique. The results are shown in Fig. 4A.
The survival rates of CSps in vivo were 54.5 ± 7.5% at
week 1, 31.0 ± 4.5% at week 2 and 16.8 ± 5.3% at
week 4. Furthermore, all DiR-labelled CSps were
distributed inside cardiac tissue, and no fluorescence was
seen in the left or right lung.
The fate of CSps in cardiac tissue after transplantation
is shown in Fig. 4B and C. At 4 weeks after trans-
plantation, DiR-labelled cells were clearly seen in cardiac
tissue sections, suggesting survival in cardiac tissue in vivo.
Specifically, these cells reached the epicardium (Fig. 4B),
and also migrated into the infarcted myocardial tissues
(Fig. 4C). These data show that the implanted CSps were
maintained well in the heart with no loss to other tissues
andwere able tomigrate tomyocardial tissue and infiltrate
into the infarcted area.
LV function and survival rate of rats after myocardial
infarction
The UCG results before and after myocardial infarction
are shown in Fig. 5 and Table 2. Figure 5A and B shows
that after myocardial infarction, AWT was smaller in the
CSps and Control groups, compared with the Sham group
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(P < 0.05). The difference in AWT between the CSps and
Control groups was not statistically significant, despite
higher absolute values at different time points (Fig. 5B).
Myocardial infarction caused an increase in LVESD as
seen in infarctionControl. However, CSps transplantation
significantly inhibited the increase in LVESD caused
by myocardial infarction with an approximately 15%
reduction, an effect which occurred with an early onset
and wasmaintained throughout the experiment (P< 0.05
vs. Control group, Fig. 5A–C). Of note, myocardial
infarction reduced LVEF but CSps transplantation
significantly increased LVEF by about 40%, an effect seen
at all the time points (Fig. 5A–D). Figure 5E shows the
number of surviving rats in the Sham, CSps and Control
groups. The survival rate was reduced to 52%4weeks after
myocardial infarction (Control). CSps administration
increased the survival rate to 80% (P < 0.05 vs. Control).
Kaplan–Meier curves for the survival of rats in the CSps
and Control groups are shown in Fig. 5E (n = 25 for each
group).
Fibrosis in non-infarcted area, viable myocardial cells
and angiogenesis in the infarcted area
Figure 6A shows that CSps significantly reduced the
infarcted size (P < 0.05). The deposition of collagen
in the non-infarcted area is shown in Fig. 6B. Masson
staining revealed that myocardial infarction resulted in
myocardial fibrosis in the non-infarcted area. CVF was
increased significantly in the Control group (11.5 ± 2.1
%) compared with the Sham group (1.8 ± 0.8 %)
4 weeks after myocardial infarction. CSps transplantation
significantly inhibited the increase in CVF in the
non-infarcted area with a 50% reduction (5.8 ± 1.1%,
P < 0.05).
Myocardial cell viability in the infarcted area 4 weeks
after myocardial infarction is shown in Fig. 6C. Four
weeks after myocardial infarction, there was an apparent
uptake defect in the anterolateral wall of the left ventricle
in Control rats (as shown by Gao et al. 2012) with
F-FDG under micro-PET/CT (Fig. 6C). However, the
uptake rate of F-FDG was 2.5-fold higher in the CSps
group (0.622 ± 0.064%ID g–1 vs. 0.246 ± 0.059 %ID g–1
in the Control group, P < 0.05). This suggests that
there were significantly more living cells following CSps
administration. Further immunofluorescence determined
the expression of myocardial cells (cTnT-positive) and
blood vessels (α-SMA-positive) 4 weeks after myo-
cardial infarction. Figure 6D shows that compared with
the Control group, CSps transplantation significantly
increased the expression of cTnT in the infarcted area,
and quantitative image analysis shows that the Integrated
Optical Density (IOD) of cTnTwas 8884.5± 1063.8 in the
CSps group compared with 1872 ± 463.5 in the Control
group (P < 0.05), demonstrating a large effect on myo-
cardial cell regeneration. The effect of transplantation of
CSps on angiogenesis in the infarct area is shown inFig. 6E.
The vascular density was also significantly higher in the
CSps group (7 ± 2 per field) than in the Control group
(3 ± 1 per field) (P < 0.05).
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overlap with α-SMA-labelled vessel; D, BrdU and α-SMA staining showing the vessels were newly formed. Areas
of blood vessels indicated by a star were enlarged as indicated by the arrows. E, contents of growth factors in
fluid of the pericardial cavity. ∗P < 0.05 versus Control group.
Mechanisms of action – direct differentiation of CSps
into cardiac myocytes and the paracrine effect
To explore the mechanisms of action underlying the
myocardial regenerative effect of CSp administration,
we examined the differentiation of DiR-labelled CSps
into cardiomyocytes and development of blood vessels
by direct immunofluorescence. Figure 7A shows that
transplanted DiR-labelled CSps survived and infiltrated
into the epicardium, and co-staining DiR-labelled cells
with cTnT was also seen. The distribution of DiR
only in DAPI-positive areas excluded the possibility of
non-specific DiR dye leak into the acellular dead space.
These data suggest that CSps can directly differentiate into
myocardial cells after transplantation in vivo. Figure 7B
shows that CSps migrated into the infarcted myocardial
tissue. The cTnT-positive cells can be seen to be alongside
the DiR-labelled cells but rarely co-stained with DiR.
These results imply that CSps were able to promote the
formation of cardiac muscle cells through a paracrine
effect. In the present study, the mechanism by which CSps
promote angiogenesis was also investigated. Figure 7C
shows α-SMA-positive cells around theDiR-labelled CSps
at the infarcted site, but there were no cells that expressed
both α-SMA and DiR. Figure 7D shows additional BrdU
staining, confirming that these vessels were newly formed.
These results suggest that transplantation of CSps in vivo
can promote angiogenesis in infarcted myocardial tissue
via a paracrine action.
To ascertain the potential sources of paracrine
mediators, the content of growth factors, VEGF, bFGF,
HGF and IGF-1, in pericardial cavity liquid was measured
by ELISA 1 and 4 weeks after myocardial infarction.
Figure 7D shows that contents of VEGF, bFGF, HGF
and IGF-1 in pericardial effusion of the CSps group
were significantly higher than those in the infarction only
Control group 1 and 4 weeks after myocardial infarction.
VEGF, bFGF, HGF and IGF-1 contents in the CSps group
were 3.06, 8.75, 1.61 and 2.54 times those in the Control
group, respectively (P < 0.05) at 1 week after myocardial
infarction (see also Table 1). At 4 weeks after myocardial
infarction, VEGF, bFGF, HGF and IGF-1 contents in the
CSps group were 1.96, 3.12, 2.01 and 3.66 times those
in the Control group, respectively (P < 0.05). These
quantitative data indicate a large increase of the growth
factors followingCSpadministration.Thesedata therefore
show that CSps intervention significantly enhanced the
production of growth factors in the pericardial cavity,
which could serve as paracrine mediators to stimulate
proliferation and differentiation of cardiac muscle and
blood vessels in the infarcted myocardium.
Discussion
The results from the present study demonstrated that:
(1) matrix hydrogel protected CSps against apoptosis
and necrosis in vitro for up to 12 h; (2) 50% PFMI
pretreatment enhanced the efficacy of CSps without
affecting cell viability; (3) transplantation of matrix
hydrogel-packaged, 50% PFMI-pretreated CSps into the
pericardial cavity improved cardiac function and myo-
cardial fibrosis following myocardial infarction, increased
the survival ofmyocardial cells andpromotedangiogenesis
in the infarcted area: and (4)mechanistically, formation of
cardiacmuscle cells wasmediated by direct differentiation
of CSps as well as their paracrine action – angiogenesis was
via a paracrine effect. To our knowledge, this is the first
study that has administered pre-optimized CSps via the
pericardial cavity, demonstrated the effect of functional
and morphological improvement following myocardial
infarction and examined the underlying mechanisms.
Cardiospheres as the therapeutic target stem cell
Previous studies have shown that CSps obtained from in
vitro culture can simulate the growth microenvironment
of cardiac stemcells in thebody (Li et al. 2010),whichhelps
the maintenance of cardiac stem cells. Our data show that
the three cardiac stem cell markers c-kit, sca-1 and KDR
were all expressed in the centre of CSps, which mimics
the particular structure of cardiac stem cells in their
growth microenvironment in vivo. These results further
demonstrate that CSps can maintain the characteristics
of cardiac stem cell. We noted that the locations of c-kit,
sca-1 and KDR were different (Fig. 1) but the biological
implication of this is currently not known. Our data also
show that in P0–P2 generations, a greater number of CSps
were formed, and the gene expression of growth factors
VEGF, bFGF, HGF and IGF-1 remained high. However,
from P3 onwards, the number of CSps and the expression
of growth factors started to decline. Therefore, the P2
generation of CSps was chosen as the target CSps for
transplantation in vivo. This may be of relevance for CSps
application in future studies.
Matrix hydrogel packing for CSps in vivo
transplantation
In clinical treatment, transport of stem cells from the
laboratory to the operating theatre takes time. Ensuring
the survival rate of stem cells during this period is an
important factor in stem cell therapy (Chen et al. 2013).
In previous studies, cold PBS was used to collect and
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Table 1. Content of growth factors in fluid of the pericardial cavity
CSps group Control group
Week 1 Week 4 Week 1 Week 4
VEGF (pg mL–1) 909.0 ± 85.1∗∗ 65.3 ± 22.5∗∗ 297.4 ± 53.6 33.2 ± 12.2
bFGF (pg mL–1) 318.5 ± 58.9∗∗ 83.9 ± 11.2∗∗ 36.4 ± 6.9 26.9 ± 6.2
IGF-1 pg mL–1) 14368.1 ± 423.4∗∗ 4786.1 ± 337.1∗∗ 5659.5 ± 382.5 1307.3 ± 247.8
HGF (pg mL–1) 2158.5 ± 167.6∗∗ 339.4 ± 64.2∗∗ 1338.6 ± 129.7 169.2 ± 36.2
∗∗P < 0.01 versus the control group at the same time point
Table 2. Two-way ANOVA of cardiac function variables
Sham Control
AWT
Week 0 Control 0.559 –
CSps 0.807 0.732
Week 1 Control 0.002 –
CSps 0.045 0.169
Week 2 Control 0.002 –
CSps 0.034 0.204
Week 4 Control <0.001 –
CSps 0.002 0.075
LVESD
Week 0 Control 0.172 –
CSps 0.742 0.290
Week 1 Control <0.001 –
CSps <0.001 0.004
Week 2 Control <0.001 –
CSps <0.001 0.011
Week 4 Control <0.001 –
CSps <0.001 0.002
LVEF
Week 0 Control 0.556 –
CSps 0.874 0.457
Week 1 Control <0.001 –
CSps <0.001 <0.001
Week 2 Control <0.001 –
CSps <0.001 <0.001
Week 4 Control <0.001 –
CSps <0.001 <0.001
store stem cells before transplantation in vivo (Tseliou
et al. 2014). However, the survival state of the cells during
this period has never been assessed. The present study
assessed the viability of stem cells and found that CSps
in PBS at 4°C began to become apoptotic after 1 h in
vitro. The proportion of living cells continued to decline
with time. After 6 and 12 h, living cells comprised only
86.35 ± 1.65 and 44.48 ± 1.45%, respectively. The pre-
sent study assessed the protective effect of matrix hydrogel
on CSps in vitro. The survival rate of CSps in the matrix
hydrogel was significantly increased; the proportion of
living CSps was 92.38 ± 1.43% after 12 h in vitro at 4°C
(Fig. 2). Thus, matrix hydrogel can protect CSps against
apoptosis or necrosis in vitro for up to 12 h. We therefore
used CSps packaged bymatrix hydrogel to be transplanted
in vivo. These data suggest that matrix hydrogel can be
a useful vehicle for maintaining viability during trans-
portation of CSps stem cells.
Enhancing CSps efficacy by PFMI pretreatment for
in vivo transplantation
Following transplantation into the heart after myocardial
infarction, the adverse living environment, especially
hypoxia and inflammation, imposes a significant stress
to CSps (Khan et al. 2010). To increase the survival and
proliferation of stem cells after transplantation, many
strategies have been explored previously. It was reported
(Rosova et al. 2008; Yan et al. 2012) that hypoxic pre-
conditioning could increase the survival and functioning
of stem cells in vitro and in vivo after transplantation.
In the present study, stem cells had to be transplanted
into the pericardial cavity after myocardial infarction
and survival in this post-myocardial infarction PF was a
significant challenge. A key question was how to improve
the survival of CSps and promote their efficacy. We
hypothesized that pretreatment of CSps with the PF
from another subject undergoing myocardial infarction
would enhance the ability of CSps to endure a sub-
sequent myocardial infarction environment. CSps were
pretreated with PFMI at different concentrations for
24 h in vitro. We found that 50% PFMI pretreatment
significantly enhanced the biological activity of CSps, and
also had no adverse effect on cell viability. Specifically, pre-
treatment with 50% PFMI enhanced mRNA expression
of stem cell genes and differentiation of cardiac muscle
cells, and promoted the expression of growth factor
genes. These outcomes suggest that a high efficacy of
CSps can be obtained by pretreatment with PFMI, a
useful finding for stem cell therapy. The factors mediating
the conditioning of CSps are unknown. Whether some
ischaemia- and tissue-necrosis-stimulated growth factors
play a role remains to be established. Furthermore, this
PF conditioning effect is only observed on the CSps
in vitro. Whether the observed enhancement of CSp
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activity directly contributes to myocardial regeneration
requires further in vivo experiments by comparing the
CSp implants.
The pericardial cavity as the delivery route for CSps
The present study directly introduced CSps to the heart
in vivo by intrapericardial administration. CSps have been
showntoproduce stemcellswithbetter regenerative ability
and low arrhythmogenicity, but have never been directly
administrated via the pericardium to treat myocardial
infarction. We have chosen the intrapericardial route for
an important reason: as a solid cell cluster, CSps have
the risk of entering the blood circulation and result in
embolism if being delivered through intracoronary artery
infusion (IC), interstitial retrograde coronary venous
infusion (IRV) or intravenous infusion (IV) delivery
routes; however, the pericardial cavity can retain the
CSps, prevent microthrombolization and also limit
the loss of stem cells into other tissue or the circulation.
The results show that pericardial administration of CSps
is safe. Of particular significance, we have also assessed the
therapeutic potential of this manoeuvre for myocardial
infarctionwith a 4-week period of observation. The in vivo
survival rate of DiR-labelled CSps at different time points
was assessed by a small animal in vivo imaging technique.
The survival rate of CSps in vivo was 54.5 ± 7.5% at week
1, 31.0 ± 4.5% at week 2, and 16.8 ± 5.3% at week 4,
much higher than the 2–11% retention rates for stem
cells through other conventional routes of delivery (Hou
et al. 2005). This demonstrates high retention and survival
rate of CSps by intrapericardial delivery. We have also
observed that all DiR-labelled CSps were retained in heart
tissue, with no leak to the left or right lung, in contrast to
25–50% of the delivered stem cells entering the lung (Hou
et al. 2005). In addition, we have traced the outcome of
CSps in cardiac tissue after transplantation and found that
after 4 weeks of transplantation, significant DiR-labelled
cells survived in cardiac tissue sections. Importantly, these
cells reached the epicardium, and also migrated into the
infarcted myocardial tissues. These cells were thus able to
contribute tomyocardial regeneration. Theuse of the peri-
cardial route to implant isolated stem cells has also been
reported by two groups in previous studies (Saltzman
et al. 2010; Blazquez et al. 2015, 2016) but no study has
explored this route for application of CSps. Saltzman et al.
(2010) tested endothelial progenitor cells for their ability
to migrate into the area of infarct myocardium but did
not examine myocardium-derived stem cells. Blazquez
et al. (2015, 2016) reported migration into the myocardial
infarction zone by mesenchymal stem cells in one study
and the safety of intrapericardial administration of iso-
lated stem cells derived from CSps in another, although
myocardium regeneration and ventricular function were
not examined. Our findings provide the first evidence
for the effective migration and incorporation into the
infarcted myocardium by the CSps, which has distinct
advantages over isolated stem cells from the CSp as
discussed earlier
Effect of CSp transplantation on myocardial infarction
The present study has shown that transplantation of these
pre-optimized and matrix hydrogel-protected CSps into
the pericardial cavity produced a significant therapeutic
effect. (1) CSp transplantation improved cardiac function,
as evidenced by significant improvements in LVESD,
LVEF and survival rate. (2) This intervention ameliorated
myocardial infarction-induced myocardial fibrosis in the
non-infarcted area. (3) CSp transplantation increased
surviving myocardial cells, as shown by the higher uptake
rate of F-FDG in the CSp group revealed by micro-
PET/CT. (4) This protocol allowed CSps stem cells to
differentiate intomyocardial cells, as shown by co-staining
cTnT and DiR (see below). (5) This treatment promoted
angiogenesis in the infarcted area 4 weeks after myo-
cardial infarction, as seen by increased α-SMA-positive
staining in the CSps group. These data provide compelling
evidence that pericardial CSps transplantation has high
therapeutic potential for myocardial infarction. This is
the first study that systematically examined myocardial
remodelling and ventricular function in an experimental
model of myocardial infarction by pericardial application
of CSps and demonstrated consistent beneficial effects
on all variables. A previous study under comparable
experimental conditions using the SD rat model of myo-
cardial infarction with a 4 week follow-up showed that
adipose-derived stem cells improved LVEF by 20% while
bone-marrow-derived stem cells had no effect; none of
these cells reduced LVESD (Rasmussen et al. 2014). The
40 and 15% improvements on ejaculation fraction and
end systolic diameter by CSps in our study demonstrate
an advantage over other stem cell therapies in this earlier
study.
Direct differentiation and paracrine action as
mechanisms of regeneration
The present study examined direct differentiation of CSps
into cardiomyocytes in vivo and as well as their indirect
effect on cardiac cell proliferation and angiogenesis by
DiR labelling in combination with immunofluorescence.
We found that some transplanted DiR-labelled CSps were
also cTnT-positive. This demonstrates that CSps can
differentiate into cardiac muscle cells directly after trans-
plantation in vivo. Therewas also significant accumulation
of cTnT-positive cells around DiR cells but they were
not co-stained with DiR, consistent with CSps exerting
an indirect trophic effect on adjacent cardiac cells by
paracrine action. However, no cells co-expressed α-SMA
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and DiR. This suggests that CSps do not differentiate
into blood vessels directly. Instead, a large number of
α-SMA-positive cells, whichwere not co-stainedwithDiR,
surrounded DiR-labelled cells. These data suggest that the
increase in blood vessels was mediated by a mechanism of
paracrine effect. Both direct differentiation and paracrine
effect are important underlyingmechanisms for improved
cardiac function and remodelling by intrapericardial
CSps. We also investigated potential mediators which
could augment the efficacy CSps themselves in the peri-
cardial cavity and generate a paracrine effect in the
infarcted myocardium. Direct assessment of the content
of growth factors showed that VEGF, bFGF, HGF and
IGF-1 in pericardial effusion from the CSps group were
many fold higher than those from the Control group at
both early and late time points aftermyocardial infarction.
These findings demonstrate that CSps transplantation can
increase these growth factors in the pericardial space,
which could serve as paracrine mediators to promote
myocardial cell growth and angiogenesis in the infarcted
area. The ability of these growth factors to promote myo-
cardial regeneration and angiogenesis has been described
by previous studies (Segers & Lee, 2010; Marsano et al.
2013; Chen et al. 2015). More specific experiments are
required to identify the mediators responsible for the
paracrine stimulation of myocardial regeneration by peri-
cardial CSps implantation.
Conclusions
Pretreatment of CSps with PFMI can enhance mRNA
expression of stem cell genes and differentiation of cardiac
muscle cells, and promote expression of growth factor
genes; this suggests that high biological activity of CSps
can be obtained by PFMI treatment. Matrix hydrogel
can protect CSps against apoptosis and necrosis in vitro
for up to 12 h. Transplantation of PFMI-preconditioned,
matrix hydrogel-protectedCSps into the pericardial cavity
can improve cardiac function, reduce myocardial fibrosis,
increase the survival of myocardial cells and promote
angiogenesis in the infarcted area. Mechanistically, CSps
can be directly differentiated into cardiac myocytes in
vivo, and promote regeneration of cardiac myocytes and
blood vessels in the infarcted area through a paracrine
mechanism. This is the first application of modulatable
CSps implantation into the pericardial cavity to treatmyo-
cardial infarction in an experimentalmodel with a positive
outcome.
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